In Brief
This article was originally published in The Rose Sheet
Executive Summary
RIFM Requests Ingredient Info
You may also be interested in...
Outlook Is Cheery For Designer Fragrances This Holiday Season – NPD
This holiday season, designer fragrances are expected to compete more effectively against similarly priced electronics than they have in recent years, according to NPD Group Vice President and Global Industry Analyst Karen Grant.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.